New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
13:46 EDTOPXAOpexa Therapeutics held a conference call
Conference call to discuss the option and license agreement with Merck Serono for development of Tcelna for treatment of Multiple Sclerosis was held on February 5 at 8:30 am and has a webcasted replay available. Webcast Link
News For OPXA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
08:10 EDTOPXAOpexa Therapeutics to present biomarker data from NMO patients at AAN meeting
Opexa Therapeutics announced that it has been invited to present data on the immune profile of patients with NMO at the 67th American Academy of Neurology Annual Meeting in Washington D.C. Opexa will present the results of a study conducted to characterize the cellular immune profile of NMO patients prescribed B-cell depleting therapy in comparison to those of healthy donors. The results showed that despite administration of B-cell depleting therapy, inflammation continued to persist as did the presence of activated T-cells. Opexa has a preclinical development program in NMO and IND enabling activities are currently being conducted with its drug development candidate, OPX-212.
April 16, 2015
16:15 EDTOPXAFrigate Ventures reports 9.9% passive stake in Opexa Therapeutics
Subscribe for More Information
April 9, 2015
07:03 EDTOPXAOpexa Therapeutics announces completion of rights offering
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use